ACT Key Stats
| Income Statement | |
| Revenue TTM | 6.286B |
| Revenue Quarterly YoY Growth | 24.35% |
| EPS Diluted TTM | -0.4659 |
| EPS Diluted Quarterly YoY Growth | |
| Net Income TTM | -60.30M |
| Profitability | |
| Gross Profit Margin Quarterly | 42.70% |
| Profit Margin Quarterly | -5.42% |
| Dividend | |
| Dividend Yield | 0.00% |
| Payout Ratio TTM Pro | Go Pro |
| Current Valuation | |
| Market Cap | 16.03B |
| Enterprise Value | 22.13B |
| PE Ratio TTM | |
| PE 10 Pro | Go Pro |
| PEG Ratio | |
| Price / Book Value | 4.447 |
| Other | |
| Beta Pro | Go Pro |
| Debt to Equity Ratio | 1.781 |
| Free Cash Flow | 187.20M |
| Return on Equity | -1.64% |
ACT News
- IBD 50: Top 5 Medical Stocks Include Celgene, Actavis May 18
- Actavis Could Lower Tax Rate With Warner Chilcott Deal May 17
- Actavis (ACT) Says Will Pursue Bid for Warner Chilcott plc (WCRX) - Reuters Street Insider May 17
- Warner Chilcott buy may be Actavis' best takeover defense May 17
- DEALTALK: Warner Chilcott buy may be Actavis' best takeover defense May 17
- S&P 500 Stocks Biggest Weekly Changes in Target Price May 17
- Following Up an Acquisition With an Even Larger Merger? May 16
- Apple Hits App Milestone, U.S. Bancorp Execs Unload, and 3 More Hot Stocks May 16
- Drugmaker Actavis' shares up May 16
- S&P 500 Stocks Farthest Above 50-DMAs May 16
ACT Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Actavis is up 79.52% over the last year vs S&P 500 Total Return up 31.68%, Valeant Pharmaceuticals International up 66.21%, and Warner Chilcott up 29.22%.
ACT Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these ACT related companies
Pro Ratings for ACT
Pro Report PDF for ACT
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.
Download ACT Pro Report PDF
Pro Strategies Featuring ACT
Did Actavis make it into our Pro Portfolio Strategies?
ACT Profile
Exchange: NYSE
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing, and distributing generic, brand, and biosimilar products. The Company has global and U.S. headquarters in Parsippany, New Jersey, and international headquarters in Zug, Switzerland.
Other ACT Resources
- Wiki Page
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ACT | 125.50 | +1.89 | +1.53% | 16.03B |
